Drug profile · INN
cenegermin-bkbj
OXERVATE
cenegermin-bkbj (OXERVATE) is a neurotrophic tyrosine kinase receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — cenegermin-bkbj
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
cenegermin-bkbj (OXERVATE) is a neurotrophic tyrosine kinase receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Neurotrophic tyrosine kinase receptor agonist
Primary target: Neurotrophic tyrosine kinase receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is cenegermin-bkbj?
cenegermin-bkbj (OXERVATE) is a neurotrophic tyrosine kinase receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for cenegermin-bkbj?
OXERVATE is a marketed brand name for cenegermin-bkbj. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cenegermin-bkbj?
cenegermin-bkbj has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.